Amid a structural shift towards Asia, Insilico Medicine's IPO in December was a significant moment for the exchange, while French biotech TheraVectys is understood to be considering a listing.

In a positive year for the region's banks, 2025 ECM fees in Apac, ex Japan, were up 45% from 2024, DCM fees saw 11% growth, amid a record year for bonds, while M&A advisory fees climbed 43%.

The HK$155 a share offer is a 33% premium over Hang Seng's 30-day average closing price; HSBC already owns 63% of the HKEX-listed bank. Hang Seng's after tax profits declined 30% in H1 2025. HSBC has paused buybacks.

Hong Kong-listed biotech firms are outperforming as Trump’s policies cause firms to change course from their traditional US destination, with more HKEX listings expected in the second half of 2025; experts shared their views at BIOHK.

From financial knowledge to government support, players in Thailand and Taiwan are finding new ways to channel capital into LGBTQ+-focussed businesses across Asia.

The firm saw net asset values decline across the financial year, however net property income and revenues grew, with high occupancy rates amid challenging conditions.

Minority owner Partners Group said the IPO proceeds will be used to further grow the Hangzhou-headquartered restaurant's 493 outlets and establish a centralised food processing facility; Clifford Chance, Citi and CMB International Capital were involved in the deal.

An April review by the IMF ended without an agreement, with June the next opportunity to meet the IMF's conditions and release two tranches of loans.

The games, if they go ahead, potentially in 2027, are expected to bring economic benefits to the Greater Bay Area, including Hong Kong, and countries part of the Belt and Road Initiative.

FA reveals the market winners of Asia's Best Companies Poll 2025.